Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1Phase 1/2 1

Status

Completed 5Active not recruiting 5Unknown 3Withdrawn 2Terminated 1Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5Gynecologic 2Breast 2Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 44Squamous Cell Carcinoma of Head and Neck 19Breast Neoplasms 18Lung Neoplasms 17Colorectal Neoplasms 15Neoplasms 12Neoplasm Metastasis 12Head and Neck Neoplasms 12Ovarian Neoplasms 11Small Cell Lung Carcinoma 9Recurrence 9Sarcoma 8Pancreatic Neoplasms 8Prostatic Neoplasms 7Advanced Solid Tumors 7Urinary Bladder Neoplasms 6Triple Negative Breast Neoplasms 6Melanoma 6Lymphoma, Large B-Cell, Diffuse 6Diabetes Mellitus, Insulin-Dependent, 12 6Uterine Cervical Neoplasms 5Carcinoma, Renal Cell 5Carcinoma, Hepatocellular 5Biliary Tract Neoplasms 5Mesothelioma, Malignant 4Lymphoma, Follicular 4Lymphoma 4Fallopian Tube Neoplasms 4Esophageal Neoplasms 4Cholangiocarcinoma 4

Interventions

Sunitinib 86Sorafenib 60Everolimus 47pazopanib 46Bevacizumab 46Nivolumab 44pembrolizumab 37aldesleukin 29Interferon-alpha 26Axitinib 24temsirolimus 23cabozantinib 20Interleukin-2 19Ipilimumab 16Interferon alpha-2 15Cyclophosphamide 15fludarabine phosphate 14Gemcitabine 14Peripheral Blood Stem Cell Transplantation 11Sirolimus 10Paclitaxel 10Erlotinib Hydrochloride 10avelumab 8Radiosurgery 8Docetaxel 8Cyclosporine 8Capecitabine 8tremelimumab 7lenvatinib 7Mycophenolic Acid 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Carcinoma, Renal Cell × durvalumab × Clear all
NCT04504669 2024-11-05

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
60 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02819596 2024-11-04

CALYPSO

Queen Mary University of London

Phase 2 Completed
69 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT02762006 2024-03-18

Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma

Case Comprehensive Cancer Center

Phase 1 Completed
29 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01975831 2022-10-12

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

Ludwig Institute for Cancer Research

Phase 1 Completed
104 enrolled 23 charts
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT02118337 2021-06-01

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies

MedImmune LLC

Phase 1/2 Completed
97 enrolled 40 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡